DB Power and LPA announce strategic partnership to globally expand solutions for issuers of structured retail products

Real Time Search
CES A80 :
CES HKMI :
CES 120 :
Total Turn.

Sirnaomics Has Been Subscribed for 17,527,696 Subscription Shares, New Capital Injection to Promote Business Growth and Development

2024-10-04 13:03:00

HONG KONG, GERMANTOWN, Md., and SUZHOU, China,, Oct. 4, 2024 /PRNewswire/ -- Sirnaomics Ltd. (the "Company", together with its subsidiaries, the "Group" or "Sirnaomics"; stock code: 2257.HK), a leading biopharmaceutical company engaged in the discovery and development of advanced RNAi therapeutics, announced that the Company has entered into a subscription agreement with Dr. Poon Hung Fai ("Dr. Poon"), the subscriber. Dr. Poon intends to subscribe for 17,527,696 subscription shares at a subscription price of approximately HK$3.36 per share, representing approximately 16.7% of the issued share capital of the Company as enlarged by the allotment and issue of the subscription shares. The gross proceeds of the subscription will be approximately HK$58.9 million.

Dr. Poon's extensive experience and successful background in the biotechnology sector will help drive the Group's business development and drug R&D process, further enhancing the Group's core competitiveness. In addition, Dr. Poon's keen market insight will facilitate the Group's strategic planning and resource allocation, and help the Group achieve long-term growth and sustainable development.

Dr. Patrick Lu, Founder, Chairman of the Board and CEO of Sirnaomics, said: "We are very pleased to sign the subscription agreement with Dr. Poon, which will not only provide significant financial support to Sirnaomics, but also further optimize our shareholding structure. With Dr. Poon's extensive experience and successful track record in the biopharma industry, coupled with Sirnaomics' pioneering and solid business foundation in nucleic acid drug innovation, we believe that this strong partnership will provide the Group with great opportunities to advance its lead products and broaden its business development horizon, as well as strengthen the Group's financial health."

About Sirnaomics

Sirnaomics is an RNA therapeutics biopharmaceutical company that focuses on the discovery and development of innovative drugs for indications with unmet medical needs and large market opportunities. Sirnaomics is the first clinical-stage RNA therapeutics company to have a strong presence in both Asia and the United States. Based on its proprietary delivery technologies, a polypeptide nanoparticle RNAi platform and GalNAc RNAi platform, GalAhead™, Sirnaomics has established an enriched drug candidate pipeline. STP122G, which represents the first drug candidate utilizing the Company's GalAhead™ technology, is currently in Phase I development. The Company has also had multiple successes with oncology applications through its clinical programs for STP705 and STP707. With the establishment of the Group's manufacturing facility in China, Sirnaomics is undergoing a transition from a biotech company to a biopharma corporation. Learn more at: www.sirnaomics.com.

Link

PR Newswire News

2024-11-04
20:51:00
OSL Group Announces Acquisition of Regulated Crypto Asset Exchange CoinBest in Japan
18:16:00
Ping An Selected on Forbes' "World's Best Employer 2024" List, 2nd among China's Financial Companies
16:03:00
ShopBack Celebrates Two Years in HK - Over HK$100 Million in Cashback Rewarded to Customers
11:53:00
The AISL Harrow Scholarships Foundation Calls for Applications: A Unique Opportunity for Students Worldwide to Study A Level at Prestigious AISL Harrow Schools.
11:22:00
CNN and Hyundai Motor Company join forces to launch a new campaign celebrating changemakers and visionaries
09:00:00
WFM Asia Announces Brand Evolution, Bolstering its Commitment to Delivering Investment Excellence in Asia Pacific
2024-11-03
01:39:00
Ping An Health Achieves WONCA International Quality Dual Certifications Defining New Standards in Internet Healthcare Services
2024-11-01
23:38:00
Web3.0 Pioneering a New Financial Era: Successful Dialogue Between Financial Institutions and Web3.0 Leadership
21:06:00
Reolink's Argus 4 Pro Awarded TIME's Special Mention in Best Inventions of 2024
18:43:00
GS1 Hong Kong Summit 2024 Successfully Concluded
18:10:00
Metalpha Regains Compliance with Nasdaq's Periodic Filing Requirement
16:59:00
eCOM's data-driven innovation steers global trade finance into new waters
13:39:00
Hong Kong Top 5 "Across-the-Border Hotpot"
10:02:00
HKBN Appoints Dr Gabriel Leung as Chief Executive Officer - Enterprise Solutions
08:25:00
LianLian Global Partners with Cyberport to Offer a Rapid, Secure, and Cost-Effective Global Payment Experience
2024-10-31
22:52:00
SunAzure Introduces De Antonio as Hong Kong's Exclusive Distributor, Ushering in a New Era of Luxurious, High-Performance Yachting
21:15:00
Caravelle International Group Announces Interim Unaudited Financial Results for Period Ended April 30, 2024
21:00:00
Metalpha Reported Fourfold Jump in Notional Amount of Derivative Products for Fiscal Year 2024
20:51:00
Hang Seng Investment Celebrates the Debut of SAB Invest Hang Seng Hong Kong ETF on Saudi Exchange
20:14:00
Ping An Health Achieves WONCA International Quality Dual Certifications Defining New Standards in Internet Healthcare Services
Back to Top